

Â Â UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549Â FORM 6-KÂ REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934Â For the month of January 2025Â Commission File No.Â 001-41010Â MAINZ BIOMED N.V.(Translation of registrantâ€™s name into English)Â Robert Koch Strasse 5055129 MainzGermany(Address of principal executive office)Â Indicate by check mark whether the registrantfiles or will file annual reports under cover of Form 20-F or Form 40-FÂ Form 20-F â˜Â Â Â Â Form40-F â˜Â Â Â Â INFORMATION CONTAINEDIN THIS REPORT ON FORM 6-KÂ On January 27, 2025, Mainz Biomed N.V. (the â€œCompanyâ€)issued a press release titled â€œMainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirementsâ€ announcingthat it has regained compliance with Nasdaqâ€™s minimum equity requirement and is in compliance with all the Nasdaq listing requirements.A copy of this press release is furnished herewith as Exhibit 99.1.Â This current report on Form 6-K and the exhibithereto are hereby incorporated by reference into our registration statement on Form F-3 (no. 333-269091) as well as our registration statementon Form S-8 (no. 333-273203), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documentsor reports subsequently filed or furnished..Â Exhibit No. Â Exhibit 99.1 Â Press release titled: â€œMainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirementsâ€ Â 1 Â Â SIGNATUREÂ Pursuant to the requirements of the SecuritiesExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.Â Date: January 27, 2025 By: /s/ William J. Caragol Â Name:â€“ William J. Caragol Â Title Chief Financial Officer Â 2Â Exhibit 99.1Â Â Mainz Biomed N.V. Regains Compliance with NasdaqCapital Market Listing RequirementsÂ BERKELEY, US â€“ MAINZ, Germany â€“ January 27, 2025Â â€“Mainz Biomed NV (NASDAQ:MYN) (â€œMainz Biomedâ€ or the â€œCompanyâ€), a molecular genetics diagnostic company specializingin the early detection of cancer, announced today that on January 23, 2025, the Company received formal notice from The Nasdaq Stock MarketLLC (â€œNasdaqâ€) confirming that it has regained compliance with the minimum stockholdersâ€™ equity requirement for continuedlisting on the Nasdaq Capital Market set forth in Listing Rule 5550(b)(1). Mainz Biomed had previously received confirmation that it hadregained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Mainz Biomed is now in full compliancewith all Nasdaq continued listing requirements and will continue to be listed and traded on The Nasdaq Capital Market.Â Please visit Mainz Biomedâ€™s officialwebsite for investors at mainzbiomed.com/investors/ for more information Â Please follow us to stay up to date:Â LinkedInX (Previously Twitter)FacebookÂ About Mainz Biomed NVÂ MainzBiomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Companyâ€™s flagship productis ColoAlertÂ®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlertÂ® ismarketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatoryapproval. Mainz Biomedâ€™s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test basedon real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more,visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.Â Â Â For media inquiriesÂ MC Services AGAnne Hennecke/ Simone Neeten+49 211 529252 20mainzbiomed@mc-services.euFor investor inquiries, please contact ir@mainzbiomed.comÂ Forward-Looking StatementsÂ Certain statements made in this press release are â€œforward-lookingstatementsâ€ within the meaning of the â€œsafe harborâ€ provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as â€œanticipateâ€, â€œbelieveâ€, â€œexpectâ€, â€œestimateâ€, â€œplanâ€, â€œoutlookâ€, and â€œprojectâ€ and other similar expressions that predictor indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the currentanalysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relyingon forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Companyâ€™s expectationsor projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-lookingstatements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) theeffect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein,as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities andExchange Commission (the â€œSECâ€) by the Company. Additional information concerning these and other factors that may impactthe Companyâ€™s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form20-F filed on April 9, 2024. The Companyâ€™s SEC filings are available publicly on the SECâ€™s website at www.sec.gov. Any forward-lookingstatement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of thedate on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral,that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.Â Â Â Â